Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma.
Noel R, Zemmour C, Montes de Oca C, Belmecheri N, Aurran-Schleinitz T, Coso D, Lopez Almeida L, Mescam L, Vey N, Bladé JS, Slama B, Bouabdallah R, Schiano de Colella JM. Noel R, et al. Among authors: mescam l. Hematology. 2023 Dec;28(1):2207948. doi: 10.1080/16078454.2023.2207948. Hematology. 2023. PMID: 37133334 Free article. Clinical Trial.
EBV+ diffuse large B-cell lymphoma associated with chronic inflammation expands the spectrum of breast implant-related lymphomas.
Mescam L, Camus V, Schiano JM, Adélaïde J, Picquenot JM, Guille A, Bannier M, Ruminy P, Viailly PJ, Jardin F, Bouabdallah R, Brenot-Rossi I, Bohers E, Robe C, Laurent C, Birnbaum D, Wotherspoon A, Gaulard P, Xerri L. Mescam L, et al. Blood. 2020 May 28;135(22):2004-2009. doi: 10.1182/blood.2019003408. Blood. 2020. PMID: 32110798 Free article. No abstract available.
Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.
Laurent C, Nicolae A, Laurent C, Le Bras F, Haioun C, Fataccioli V, Amara N, Adélaïde J, Guille A, Schiano JM, Tesson B, Traverse-Glehen A, Chenard MP, Mescam L, Moreau A, Chassagne-Clement C, Somja J, Escudié F, André M, Martin N, Lacroix L, Lemonnier F, Hamy AS, Reyal F, Bannier M, Oberic L, Prade N, Frénois FX, Beldi-Ferchiou A, Delfau-Larue MH, Bouabdallah R, Birnbaum D, Brousset P, Xerri L, Gaulard P. Laurent C, et al. Among authors: mescam l. Blood. 2020 Jan 30;135(5):360-370. doi: 10.1182/blood.2019001904. Blood. 2020. PMID: 31774495 Free PMC article.
Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F, Gonçalves A, Guille A, Adelaïde J, Garnier S, Carbuccia N, Billon E, Finetti P, Sfumato P, Monneur A, Pécheux C, Khran M, Brunelle S, Mescam L, Thomassin-Piana J, Poizat F, Charafe-Jauffret E, Turrini O, Lambaudie E, Provansal M, Extra JM, Madroszyk A, Gilabert M, Sabatier R, Vicier C, Mamessier E, Chabannon C, Pakradouni J, Viens P, André F, Gravis G, Popovici C, Birnbaum D, Chaffanet M. Bertucci F, et al. Among authors: mescam l. Genome Med. 2021 May 18;13(1):87. doi: 10.1186/s13073-021-00897-9. Genome Med. 2021. PMID: 34006291 Free PMC article. Clinical Trial.
Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation.
Laurent C, Syrykh C, Hamon M, Adélaïde J, Guille A, Escudié F, Jalowicki G, Fina F, Bardet A, Mescam L, Molina TJ, Dartigues P, Parrens M, Sujobert P, Besson C, Birnbaum D, Xerri L. Laurent C, et al. Among authors: mescam l. Am J Surg Pathol. 2022 Jun 1;46(6):742-753. doi: 10.1097/PAS.0000000000001834. Epub 2021 Nov 18. Am J Surg Pathol. 2022. PMID: 34799485
Giant Pedunculated Hepatic Hemangioma: A Case Report and Literature Review.
Al Farai A, Mescam L, De Luca V, Monneur A, Perrot D, Guiramand J, Delpero JR, Bertucci F. Al Farai A, et al. Among authors: mescam l. Case Rep Oncol. 2018 Jul 16;11(2):476-484. doi: 10.1159/000490696. eCollection 2018 May-Aug. Case Rep Oncol. 2018. PMID: 30140210 Free PMC article.
Response to trametinib of histiocytosis with an activating PTPN11 mutation.
Farnault L, Hélias-Rodzewicz Z, Venton G, Fanciullino R, Gabriel S, Mescam L, Haroche J, Donadieu J, Emile JF. Farnault L, et al. Among authors: mescam l. Leuk Lymphoma. 2020 Jan;61(1):194-197. doi: 10.1080/10428194.2019.1650175. Epub 2019 Aug 8. Leuk Lymphoma. 2020. PMID: 31393194 No abstract available.
19 results